Records containing: Relapse Multiple Myeloma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-14
Phase I Study of FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2026-03-23
Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2026-03-23
MUltiple Myeloma Italian ObServational sTudy (MUST)
CLINICAL_TRIALS study record update · 2026-03-13
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2026-01-29
Phase I Study of Vaccination With DC/MM Fusion Cells in Combination With BCMA Directed CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2026-01-22
A Multicenter Clinical Study of Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2026-01-05
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2025-12-22
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
CLINICAL_TRIALS study record update · 2025-10-01
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
CLINICAL_TRIALS study record update · 2025-09-02
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2025-07-15
A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2025-07-09
Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2025-04-01
Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse
CLINICAL_TRIALS study record update · 2025-01-28
A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2024-12-18
Free Regimen of Dexamethasone as Initial Therapy for Advanced Relapsed/Refractory Multiple Myeloma: an Open-label Randomized, Non-inferiority, Controlled Trial
CLINICAL_TRIALS study record update · 2024-11-12
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2024-01-31
A Phase 1/2, Open-Label, Dose Escalation and Confirmation Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
CLINICAL_TRIALS study record update · 2023-07-18
Multiple Myeloma Patient Registry - Prospective National Multi Center Prospective Study
CLINICAL_TRIALS study record update · 2022-06-24
Clinical Trial for the Safety and Efficacy of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
CLINICAL_TRIALS study record update · 2021-12-09
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2021-11-26
An Open-label Phase I, Dose Escalation Study of the Safety and Tolerability of OPD5 as Myeloablative Conditioning Regimen Followed by Autologous Stem Cell Transplant (ASCT) for Patients With Relapsed Refractory Multiple Myeloma (RRMM)
CLINICAL_TRIALS study record update · 2020-12-17
Clinical Trial for the Safety and Efficacy of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-12-10
Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
CLINICAL_TRIALS study record update · 2020-08-19
A Phase I Study of INCB053914 (Pan-PIM Kinase Inhibitor) and Pomalidomide With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2019-07-02
Patient Related Outcomes in Real Life Prospective Follow up Study: Carfilzomib in Combination for the Treatment of RR MM